vTv Therapeutics Inc. Weighted Average Shares Growth

Weighted Average Shares Growth of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Weighted Average Shares Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Weighted Average Shares Growth for the quarter ending September 29, 2020 was 50.15% (a -20.21% decrease compared to previous quarter)
  • Year-over-year quarterly Weighted Average Shares Growth decreased by -65.01%
  • Annual Weighted Average Shares Growth for 2019 was 143.33% (a 404.15% increase from previous year)
  • Annual Weighted Average Shares Growth for 2018 was 28.43% (a 1746.1% increase from previous year)
  • Annual Weighted Average Shares Growth for 2017 was 1.54% (a -89.95% decrease from previous year)
  • Twelve month Weighted Average Shares Growth ending December 30, 2019 was 154.62% (a 20.15% increase compared to previous quarter)
  • Twelve month trailing Weighted Average Shares Growth increased by 217.43% year-over-year
Trailing Weighted Average Shares Growth for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
154.62% 128.69% 93.32% 48.71%
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Weighted Average Shares Growth of vTv Therapeutics Inc.

Most recent Weighted Average Shares Growthof VTVT including historical data for past 10 years.

Interactive Chart of Weighted Average Shares Growth of vTv Therapeutics Inc.

vTv Therapeutics Inc. Weighted Average Shares Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 50.15% 62.85% 90.1%
2019 143.33% 161.06% 178.99% 135.7% 143.33%
2018 28.43% 26.96% 3.68% 0.07% 28.43%
2017 1.54% 0.02% 1.34% 5.02% 1.54%
2016 15.33% 16.69% -70.93% 15.33%

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.